Covidien, Boulder, Colo, reported an increase in net sales for the second quarter of 2009, rising 11% to $2.7 billion from $2.4 billion 1 year ago, led mostly by pharmaceutical products. Despite the rise in overall net sales, the company reported lower sales in the ventilation and sleep businesses compared to last year.

Commenting on the overall performance of the company, Richard J. Meelia, chairman, president, and CEO of Covidien, said, “Despite the global economic slowdown, we delivered solid operational performance in the second quarter. Our results were driven by new products and market share gains, aided by double-digit increases in several key product lines.”